Abstract 444P
Background
In 2017, SURC was introduced in Victoria Australia responding to broader contexts challenges within the health system. SURC’s a nurse led model of care addressing and identifying gaps within an oncology service to support patients experiencing SACT toxicities during the period of active treatment. In May 2020 the Symptom & Urgent Review Clinic (SURC) commenced in Ballarat’s Regional Integrated Cancer Centre. (BRICC) provides health care in the Victorian Grampians Region covering 48,646 square kilometre area. BRICC provides three outreach cancer services to Stawell, Horsham, and Maryborough.
Methods
SURC provides a streamlined process for Oncology patients receiving SACT access to dedicated oncology nursing and medical staff through a single point of access. Patients access SURC from start of treatment, throughout their SACT and 12 weeks after treatment completion. SURC contacts all C1D5 patients, patients discharged from hospital, and shared medical/nursing model of care. SURC referrals were from the medical and nursing oncology team, allied health and other internal and external stakeholders. Patients or their carer could call SURC directly. Workforce challenges in 2022 resulted in SURC setting up a mirrored service supporting BRICC patients in Stawell and Maryborough enabling them to continue having treatment close to home and have their symptoms and toxicities addressed in a timely fashion by an advanced oncology nurse. SURC also became the point of contact for any COVID-related questions and management of patients testing COVID positive.
Results
From May 2020-April 2023 there was 6558 contacts to SURC including telephone calls, clinic presentations, same day ED and day admissions. SURC funding was outpatient WASE 40.52 data activity recorded by IBA. Pre and post SURC data for admitted patients was analysed showing inpatient stay days halved from 686 to 399, reduction in inpatient oncology visits of 104 to 70, as well as readmissions from 4-0.
Conclusions
SURC has improved quality of care and access to specialist nursing and medical advice for patients receiving SACT. SURC provides a single point of access for patients receiving SACT and has also had a significant positive impact on early symptom recognition and management in a timely manner.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Grampians Health Ballarat.
Funding
Has not received any funding.
Disclosure
S. Bartlett: Non-Financial Interests, Personal and Institutional, Member of Board of Directors: CNSA.
Resources from the same session
340P - The role of CT scans and laboratory tests for surveillance in patients with diffuse large B cell lymphoma who achieved complete remission after first-line chemotherapy
Presenter: YU Yagi
Session: Poster Display
Resources:
Abstract
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract